Yong, Keir X. X. http://orcid.org/0000-0002-9708-3599
Graff-Radford, Jonathan
Ahmed, Samrah
Chapleau, Marianne
Ossenkoppele, Rik
Putcha, Deepti
Rabinovici, Gil D.
Suarez-Gonzalez, Aida
Schott, Jonathan M.
Crutch, Sebastian
Harding, Emma
Funding for this research was provided by:
Alzheimer's Society (AS-JF-18-003)
NIH Clinical Center (R01EY027964, AG050603, P30-AG062422, R35 AG072362)
Wellcome Trust (204841/Z/16/Z)
Alzheimer's Association (ZEN-21-848216)
ESRC-NIHR (ES/S010467/1, ES/L001810/1)
NIHR (cov-lt2-0014)
Economic and Social Research Council (ES/W006014/1)
Alzheimer Society (AS-PG-14-022)
Article History
Accepted: 8 December 2022
First Online: 8 February 2023
Change Date: 21 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11940-023-00751-w
Compliance with Ethical Standards
:
: K. Y. reports personal fees from Roche outside the submitted work. G. D. R. reports grants and personal fees from GE Healthcare, grants from Life Molecular Imaging, grants and personal fees from Genentech, personal fees from Eli Lilly, personal fees from Johnson & Johnson, personal fees from Merck and personal fees from Roche, outside the submitted work, and is an Associate Editor for JAMA Neurology. J. M. S. reports personal fees from Roche Pharmaceuticals, personal fees from Eli Lilly, other from Axon Neuroscience, non-financial support from AVID Radiopharmaceuticals, other from Biogen, personal fees from Merck, other from Oxford University Press, other from Henry Stewart Talks, personal fees from Alzheimer’s Research UK and personal fees from UK Dementia Research Institute, outside the submitted work. All other authors declare no competing interests.